1 day Ago By ABMN Staff
Thermo Fisher Scientific ( NYSE:TMO – Get Free Report ) had its target price upped by equities research analysts at Bank of America from $600.00 to $675.00 in a research report issued on Monday, Benzinga reports.
The brokerage presently has a “buy” rating on the medical research company’s stock. Bank of America ‘s price target suggests a potential upside of 10.61% from the stock’s previous close.
Other equities research analysts also recently issued reports about the stock. Robert W. Baird raised their target price on shares of Thermo Fisher Scientific from $620.
00 to $632.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. Wells Fargo & Company initiated coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, August 27th.
They issued an “overweight” rating and a $670.00 target price for the company. Stifel Nicolaus lifted their price objective on shares of Thermo Fisher Scientific from $600.
00 to $615.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Raymond James lifted their price objective on shares of Thermo Fisher Scientific from $650.
00 to $660.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $650.
00 price objective (up from $600.00) on shares of Thermo Fisher Scientific in a research note on Monday, June 3rd. Four equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company.
Based on data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $632.89.
Get Our Latest Report on Thermo Fisher Scientific Thermo Fisher Scientific Price Performance Thermo Fisher Scientific ( NYSE:TMO – Get Free Report ) last released its quarterly earnings data on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.
13 by $0.24. Thermo Fisher Scientific had a net margin of 14.
69% and a return on equity of 18.22%. The firm had revenue of $10.
54 billion for the quarter, compared to the consensus estimate of $10.50 billion. During the same period last year, the firm earned $5.
15 earnings per share. The company’s quarterly revenue was down 1.4% on a year-over-year basis.
Sell-side analysts forecast that Thermo Fisher Scientific will post 21.72 EPS for the current fiscal year. Insider Buying and Selling at Thermo Fisher Scientific In other Thermo Fisher Scientific news, VP Lisa P.
Britt sold 3,624 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 26th. The shares were sold at an average price of $613.02, for a total value of $2,221,584.
48. Following the completion of the transaction, the vice president now owns 13,699 shares of the company’s stock, valued at $8,397,760.98.
The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link . In other news, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction dated Friday, July 26th.
The shares were sold at an average price of $600.85, for a total transaction of $1,201,700.00.
Following the completion of the sale, the senior vice president now owns 13,083 shares of the company’s stock, valued at $7,860,920.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website .
Also, VP Lisa P. Britt sold 3,624 shares of the business’s stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $613.
02, for a total transaction of $2,221,584.48. Following the transaction, the vice president now owns 13,699 shares in the company, valued at $8,397,760.
98. The disclosure for this sale can be found here . Over the last quarter, insiders sold 23,084 shares of company stock valued at $14,094,292.
Corporate insiders own 0.34% of the company’s stock. Hedge Funds Weigh In On Thermo Fisher Scientific A number of institutional investors and hedge funds have recently bought and sold shares of the business.
Signature Resources Capital Management LLC boosted its holdings in Thermo Fisher Scientific by 318.2% in the 2nd quarter. Signature Resources Capital Management LLC now owns 46 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 35 shares during the last quarter.
True Wealth Design LLC boosted its holdings in Thermo Fisher Scientific by 1,275.0% in the 4th quarter. True Wealth Design LLC now owns 55 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 51 shares during the last quarter.
New Millennium Group LLC acquired a new position in Thermo Fisher Scientific in the 2nd quarter valued at about $29,000. Stephens Consulting LLC boosted its holdings in Thermo Fisher Scientific by 116.0% in the 2nd quarter.
Stephens Consulting LLC now owns 54 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 29 shares during the last quarter. Finally, LifeSteps Financial Inc. purchased a new stake in shares of Thermo Fisher Scientific in the 1st quarter valued at approximately $31,000.
89.23% of the stock is currently owned by institutional investors and hedge funds. Thermo Fisher Scientific Company Profile ( Get Free Report ) Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally.
The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Recommended Stories Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter .
.
